YCCI News

Adults who share a Hispanic background and who get hospitalized for symptoms of peripheral artery disease (PAD) are more likely to only receive care at later stages of their disease, and get their treatment through the emergency department instead of early stage disease care, elective care as compared with non-Hispanic white patients.

Yale researchers have now uncovered a key part of the process that generates an additional protective layer of the cell wall of bacteria, a finding that may help reveal vulnerabilities that could be targeted by new antibiotics.

Everything you need to know about the FDA’s nicotine reduction plan.

Using a new technology they developed that delivers a specially designed cell-protective fluid to organs and tissues, the researchers restored blood circulation and other cellular functions in pigs a full hour after their deaths.

Yale researchers Akiko Iwasaki, PhD, and Harlan Krumholz, MD, are striving to solve the mysteries of long COVID, and to provide a compassionate voice for those feeling isolated and ignored by the medical community.

A new Yale study found that, among people suffering non-fatal heart attacks associated with hot weather, an outsize portion were taking beta-blockers or antiplatelet medication. The study doesn’t prove that these medications caused the heart attacks, nor that they make people more vulnerable to heart attack. Although it’s possible that they did increase the risk of heart attacks triggered by hot weather, it’s also possible that patients’ underlying heart disease explains both the prescriptions and the higher susceptibility to heart attack during hot weather.

Yale researchers have developed a new class of molecules that target some of the deadliest brain cancers while sparing healthy tissue. The discovery combines innovative synthetic chemistry and cutting-edge mechanistic studies in molecular biology, and offers a potentially powerful new approach to treating drug-resistant glioma tumors.

The experimental vaccines use engineered lipid nanoparticles to deliver mRNA to cells with “instructions” to create spike proteins from mutating variants, which the virus uses to attach to and infect cells.

First-of-its-kind initiative seeks to build trust and address systemic barriers to participation in the development of innovative medicines